As the first and only market research firm to specialize in the stem cell industry, BioInformant has released the “Global Induced Pluripotent Stem Cell (iPSC) Industry Report – Market Size, Trends, and Forecasts, 2023.” This global strategic report provides breaking coverage of the global iPSC market, including market size figures with future forecasts through 2030. [Read more…]
iPSC Technology Grows Even More Powerful and Disruptive
Since the discovery and development of induced pluripotent stem cell (iPSC or iPS cell) technology a decade ago, significant progress has been made within stem cell biology and regenerative medicine. In recent years, iPSCs have been used extensively in disease modeling, drug discovery, and cell therapy applications. Importantly, new pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
Allogeneic iPSCs Gaining Momentum Due to Ease of Access and Economies of Scale
While autologous iPSC-based cell therapies are patient-specific, allogeneic iPSC-based cell therapies use donor-derived cells as a starting material. In recent years, a greater number of allogeneic iPSC-derived cell therapies are being studied than autologous therapies. One of the advantages of allogeneic therapy is that a large number of doses can be generated simultaneously from a single batch of iPSCs and banked. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2023
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
iPSirius Announces Clinical Trial Decisions and Secures New Patents in Japan and Israel
Paris, France – iPSirius today announced its decision to focus on advanced non-small cell lung cancer as the first indication for its comprehensive stem cell-based immunotherapy in the inaugural first-in-human clinical trial. Furthermore, the company declared its intention to apply for a clinical trial licence and undertake the clinical trial in the United Kingdom, to leverage the integrated clinical infrastructure, there, as well as take advantage of the country’s extensive biotech expertise and the UK government’s commitment to innovative healthcare solutions. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 65
- Next Page »
